Gastrointestinal Stromal Tumor (GIST) Clinical Trial
Official title:
A Phase II Study of Pazopanib in Patients With Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors (GIST)
This study is being done to gather information about the safety (any harmful effects) and
effectiveness (usefulness) of Pazopanib in the treatment of Gastrointestinal Stroma Tumors
(GIST) that cannot be treated by surgery or has spread to other organs. The Food and Drug
Administration (FDA) have approved Pazopanib for the treatment of advanced kidney cancer but
it is not approved for the treatment of GIST. The investigators hope to learn about the
safety and usefulness (effectiveness) of Pazopanib for patients with GIST.
Primary Objective:
Non-progression rate based on RECIST criteria (CR+PR+SD)
Secondary Objectives:
- Response per Choi criteria
- 6 month progression-free survival
- Safety and tolerability
n/a
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02574663 -
TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors
|
Phase 1 | |
Active, not recruiting |
NCT01991379 -
MEK162 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)
|
Phase 1/Phase 2 | |
Completed |
NCT01135849 -
B-Receptor Signaling in Cardiomyopathy
|
N/A | |
Completed |
NCT00623831 -
A Phase 1 Study of Mixed Bacteria Vaccine (MBV) in Patients With Tumors Expressing NY-ESO-1 Antigen
|
Phase 1 | |
Completed |
NCT00464620 -
Trial of Dasatinib in Advanced Sarcomas
|
Phase 2 | |
Completed |
NCT01294202 -
A Study to Investigate the Safety and Efficacy of AT13387, Alone or in Combination With Imatinib, in Patients With GIST
|
Phase 2 | |
Completed |
NCT00785785 -
A Study of Nilotinib Versus Imatinib in GIST Patients
|
Phase 3 | |
Recruiting |
NCT02443948 -
Circulating Cell-free Tumor DNA in the Plasma of Patients With Gastrointestinal Stromal Tumors (GIST)
|
N/A | |
Recruiting |
NCT01034670 -
Advanced Gastrointestinal Endoscopic Imaging
|
N/A | |
Completed |
NCT00867113 -
Five Year Adjuvant Imatinib Mesylate (Gleevec®) in Gastrointestinal Stromal Tumor (GIST)
|
Phase 2 | |
Terminated |
NCT02452424 -
A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT03594422 -
A Study of HQP1351 in Patients With GIST or Other Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05453292 -
Endoscopic Ultrasound Radiofrequency Ablation for GISTs
|
N/A | |
Completed |
NCT00780494 -
Ph II of Capecitabine, Carboplatin & Bevacizumab for Gastroesophageal Junction & Gastric Carcinoma
|
Phase 2 | |
Recruiting |
NCT04557969 -
Surgery in Gastrointestinal Stromal Tumors (GISTs) for Treatment, Tumor Modeling, and Genomic Analysis
|
||
Completed |
NCT03404076 -
Unifying Advanced Treatment With Advanced Imaging
|
||
Recruiting |
NCT04821895 -
Oncogenetic Panel and Integrated Clinical Data Registry Study for Wild Type Gastrointestinal Stromal Tumor Patients
|
||
Completed |
NCT01316263 -
A Study of IMC-3G3 in Previously Treated Patients With Unresectable and/or Metastatic Gastrointestinal Stromal Tumors
|
Phase 2 | |
Terminated |
NCT00767234 -
Permission to Collect Blood Over Time for Research
|
N/A | |
Recruiting |
NCT01048281 -
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
|